Background
Introduction
Prion diseases are a group of fatal, infectious neurodegenerative diseases, which included bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and CreutzfeldtJakob disease (CJD) in humans 1, 2 . Classically, the crucial step in the transmission and propagation of prion diseases, according to the protein-only hypothesis Historically, methods to detect and diagnose prion disease have required post-mortem examination of tissue and according to the World Health Organisation (WHO) diagnostic criteria for variant CJD (vCJD), disease can only be classified as 'probable' in the presence of significant neurological deficit and confirmed as definite by means of neuropathological examination using immunohistochemical staining 5 . Despite this the use of highly sensitive western blotting has allowed the analysis of the pattern of deposition of PrP Sc in a wide variety of tissues from vCJD patients 6 including tonsil tissue obtained at post-mortem and biopsy 7 . The use of tonsil biopsy to determine if PrP Sc is present by western blotting coupled with immunohistochemistry has proved both sensitive and specific for vCJD 8 and allows patient care plans to be established, patients and families to be counselled accordingly and appropriate infection control measures implemented 9, 10 , albeit at a late stage in disease progression.
The pre-clinical phase of vCJD is currently unidentifiable, ranging from years to several decades, and presents a substantial infection risk to others via blood transfusion products, tissue and organ transplantation and other iatrogenic routes such as medical and dental procedures with contaminated instruments. Indeed blood transfusions have been shown to be an effective route of infection for BSE and scrapie in sheep 11 and vCJD in humans [12] [13] [14] . The introduction of a sensitive and specific blood based molecular diagnostic test for prion disease will provide an immediate solution to all of these problems and will facilitate early disease diagnosis and entry into therapeutic trials.
However, the detection of PrP Sc in blood is considerably more challenging than in other tissues.
Very little is known about the nature and distribution of abnormal PrP in blood. Estimates of titres vary widely but the levels of prion infectivity demonstrated in buffy coat fractions as well as plasma derived from rodent sources are low 15 , with as little as 10
LD 50 Units present in 1ml of whole blood. In addition to the extremely low concentration of disease associated PrP, the PrP C background is very high. There is a dearth of information available about the biochemical nature of disease associated PrP in blood, in particular uncertainty remains about whether pathogenic PrP in blood is protease resistant. Evidence is accumulating that challenges the belief that all forms of diseaseassociated PrP are resistant to proteolysis. Indeed, it has recently been shown that the majority of disease associated PrP may well be sensitive to proteolytic digestion with proteinase K (PK) [16] [17] [18] [19] [20] [21] . 26, 27 . Serial PMCA gave a 10,000 fold increase in sensitivity, resulting in the detection of 10ng of vCJD brain in a 100 µl PMCA reaction 27 . However, the authors report an acute compatibility issue between the seed/substrate PRNP condon 129 which remains to be overcome. The technical limitations associated with PMCA, such as the timescales involved, substrate availability and suitability and increasing evidence for the spontaneous generation of protease resistant PrP de novo 25, 28 mean that PMCA is unlikely to provide the sole technology for a prion blood screening assay. A modified PMCA approach using 
Materials and Methods

Tissues samples
Storage between prion infected and uninfected brain homogenates following denaturation ( Figure   1 ). PK digestion reduced the detectable signal from RML homogenates by up to 58%, a finding consistent with recent reported loses of signal following PK digestion 21 . ICSM10
capture and ICSM35B detection sandwich ELISA was therefore chosen for further development and adaption to a blood based assay.
Optimisation of ICSM 10 sandwich ELISA
Optimisation of sensitivity is essential if the assay is to approach the required limits of detection for the discrimination of endogenous prion infected blood from normal samples. Switching to a fluorometric detection system gave a four fold increase in sensitivity, from 2 x 10 6 ID 50 Units ml , equivalent to a 50,000 fold dilution of whole brain 6 . Serial dilution of vCJD brain homogenate into normal brain homogenate followed by spiking into whole human blood was used to determine the assay's sensitivity ( Figure 3 ). Our optimised sandwich ELISA was shown to be able to detect PrP Sc at a dilution of 2 x 10 4 LD 50 Units ml -1 (~700fg PrP Sc ) in a total volume of 10µl of whole blood.
Immunoprecipitation and detection of vCJD spiked into whole blood
To improve the sensitivity of our immunoassay for prion infection and approach detection at the concentrations of 10-100 LD 50 Units ml -1 found in blood 39 we require the ability to capture and enrich PrP Sc from large volumes of whole blood, maximising the amount of antigen per tissue sample that is applied to the ELISA. Hence we have studied the possibility of coupling an immunoprecipitation (IP) step with our discriminatory, high sensitivity ELISA as outlined in Figure 4 . To investigate the adaption of our assay to larger blood volumes we performed ICSM33 immunoprecipitation reactions on volumes up to 8 ml of whole blood spiked with either normal or vCJD brain homogenate before detection in our sandwich ELISA ( Figure 5B ).
The coupled assay was clearly able to distinguish between vCJD and normal spiked samples with a detection sensitivity of 21 pg of PrP Sc in 8mls of whole blood, corresponding to detection at a concentration of 750 LD 50 Units ml -1 or a > 2.5 million fold dilution of infected brain equivalents.
Discussion
In the years since the outbreak of BSE and the discovery of its link to vCJD 35, 40, 41 our understanding of prion pathology and biology has increased enormously. Highly sensitive and accurate methods for the diagnostic assessment of post-mortem tissues have been developed. Application of these approaches to the diagnosis of patient biopsy samples has also proved extremely successful 8 . Recent reports have indicated that tissues such as blood and urine may contain levels of infectivity much higher than previously expected 42 .
In fact, current evidence suggests that blood transfusions may provide a particularly efficient route for prion infection [11] [12] [13] [14] . Taken together with data suggesting that subclinical or carrier states exist in these diseases 43 , transmission of vCJD via transfusion or other iatrogenic means becomes an issue of concern for public health.
Due to the prolonged pre-clinical phase of vCJD the need for a rapid, molecular diagnostic test for prion infection using easily obtainable tissues or fluids is a strategic priority for UK, European and American public health bodies. However, the strict requirements for such a test prove extremely difficult to achieve. Firstly, the quantities of RML-infected and uninfected normal control CD1 brain homogenates were analysed by ICSM 10 capture and ICSM35B detection sandwich ELISA both before and after PK digestion and in a native and SDS denatured state. Effective discrimination was achieved between infected and control samples without the need for PK digestion. PK digestion reduced the observable RML signal by 58%. 
